Teva Pharmaceutical Industries (TEVA) Total Liabilities (2009 - 2026)
Teva Pharmaceutical Industries' (TEVA) quarterly Total Liabilities came in at $32.1 billion in Q2 2026, down 3.59% YoY from $33.3 billion in Q2 2025, and up 0.91% on a QoQ basis from $31.8 billion in Q1 2026.
Teva Pharmaceutical Industries (TEVA) Total Liabilities (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has 18 years of Total Liabilities data on file, last reported at $32.1 billion in Q2 2026.
- Quarterly Total Liabilities fell 3.59% year-over-year to $32.1 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $32.1 billion (down 3.59% YoY) and the FY2025 annual result came in at $32.8 billion, down 2.3% from the prior year.
- Total Liabilities rose to $32.1 billion in Q2 2026, from $31.8 billion in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $36.8 billion in Q1 2022 to a low of $31.8 billion in Q1 2026.
- A 5-year average of $34.3 billion and a median of $34.8 billion in 2022 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2024 — Total Liabilities gained 1.92% — and 2025, when it fell 8.75%.
- Tracing TEVA's Total Liabilities over 5 years: stood at $35.4 billion in 2022, then fell by 0.17% to $35.4 billion in 2023, then declined by 4.94% to $33.6 billion in 2024, then decreased by 2.3% to $32.8 billion in 2025, then retreated by 2.24% to $32.1 billion in 2026.
- The last three Total Liabilities figures came in at $32.1 billion (Q2 2026), $31.8 billion (Q1 2026), and $32.8 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | -21.66 Bn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | 32.10 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | 11.93 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 50.85 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 819.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 20.78 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 1.67 Bn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 6.97 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 2.12 Bn |
| 10 | Alkermes | 8.12 Bn | 7.46 Bn | 397.90 Mn | 2.58 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 32.10 Bn |
| Mar 31, 2026 | 31.81 Bn |
| Dec 31, 2025 | 32.83 Bn |
| Sep 30, 2025 | 32.60 Bn |
| Jun 30, 2025 | 33.30 Bn |
| Mar 31, 2025 | 32.15 Bn |
| Dec 31, 2024 | 33.61 Bn |
| Sep 30, 2024 | 35.38 Bn |
| Jun 30, 2024 | 34.77 Bn |
| Mar 31, 2024 | 35.23 Bn |
| Dec 31, 2023 | 35.35 Bn |
| Sep 30, 2023 | 34.71 Bn |
| Jun 30, 2023 | 35.51 Bn |
| Mar 31, 2023 | 34.96 Bn |
| Dec 31, 2022 | 35.41 Bn |
| Sep 30, 2022 | 34.75 Bn |
| Jun 30, 2022 | 36.12 Bn |
| Mar 31, 2022 | 36.80 Bn |
| Dec 31, 2021 | 36.42 Bn |
| Sep 30, 2021 | 36.40 Bn |